Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells $299,280.40 in Stock

Key Points

• Stoke Therapeutics Director Edward Md Kaye sold 14,860 shares for a total of $299,280.40, reducing his ownership by 9.75%.
• The company's stock price is currently $19.77, with a 52-week range between $5.35 and $20.45.
• Equities analysts have a consensus rating of "Buy" for Stoke Therapeutics, with a target price averaging $25.57.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward Md Kaye sold 14,860 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total value of $299,280.40. Following the transaction, the director directly owned 137,581 shares in the company, valued at approximately $2,770,881.34. This represents a 9.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stoke Therapeutics Stock Performance

STOK traded up $0.18 during trading on Wednesday, reaching $19.77. The company's stock had a trading volume of 1,307,730 shares, compared to its average volume of 810,410. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $20.45. The company's fifty day moving average price is $14.42 and its 200-day moving average price is $10.83. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of 23.26 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Equities analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

STOK has been the subject of several research reports. Wedbush boosted their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. Jefferies Financial Group began coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a "buy" rating and a $30.00 price objective for the company. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. HC Wainwright cut their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, BTIG Research set a $28.00 target price on Stoke Therapeutics and gave the company a "buy" rating in a research note on Monday, August 18th. Two analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $25.57.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of STOK. RTW Investments LP increased its holdings in Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after buying an additional 471,240 shares during the period. Toronto Dominion Bank bought a new position in Stoke Therapeutics in the 4th quarter valued at approximately $35,001,000. Vanguard Group Inc. raised its holdings in Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company's stock worth $18,515,000 after purchasing an additional 53,004 shares during the last quarter. Marshall Wace LLP raised its holdings in Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company's stock worth $26,111,000 after purchasing an additional 168,771 shares during the last quarter. Finally, Siren L.L.C. increased its stake in shares of Stoke Therapeutics by 12.4% in the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock valued at $14,945,000 after acquiring an additional 247,347 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.